RESUMO
Objective: This study aimed to evaluate the effect of isolated vitamin D (VD) supplementation on the metabolic syndrome (MetS) risk profile in postmenopausal women.Methods: In this double-blind, placebo-controlled trial, 160 postmenopausal women aged 50-65 years were randomized into two groups: VD group, supplementation with 1000 IU vitamin D3/day (n = 80); or placebo group (n = 80). The intervention time was 9 months, and the women were assessed at baseline and endpoint. Clinical and anthropometric data were collected. Biochemical parameters, including total cholesterol, high-density lipoprotein, low-density lipoprotein, triglycerides, glucose, and insulin, were measured. The plasma concentration of 25-hydroxyvitamin D (25(OH)D) was measured by high-performance liquid chromatography.Results: After 9 months, there was a significant increase in the 25(OH)D levels for VD group (+45.4%, p < 0.001), and a decrease (-18.5%, p = 0.049) in the placebo group. In the VD group, a significant reduction was observed in triglycerides (-12.2%, p = 0.001), insulin (-13.7%, p = 0.008), and the homeostasis model assessment of insulin resistance (-17.9%, p = 0.007). In the placebo group, there was an increase in glucose (+6.2%, p = 0.009). Analysis of the risk adjusted for age, time since menopause, and body mass index showed that women supplemented with VD had a lower risk of MetS (odds ratio [OR] 0.42; 95% confidence interval [CI] 0.21-0.83), hypertriglyceridemia (OR 0.43; 95% CI 0.22-0.85), and hyperglycemia (OR 0.23; 95% CI 0.10-0.52) compared to the placebo group (p < 0.05).Conclusions: In postmenopausal women with VD deficiency, isolated supplementation with 1000 IU vitamin D3 for 9 months was associated with a reduction in the MetS risk profile. Women undergoing VD supplementation had a lower risk of MetS, hypertriglyceridemia, and hyperglycemia.
Assuntos
Síndrome Metabólica/prevenção & controle , Pós-Menopausa , Deficiência de Vitamina D/tratamento farmacológico , Vitamina D/administração & dosagem , Vitaminas/administração & dosagem , Idoso , Biomarcadores/sangue , Suplementos Nutricionais , Feminino , Humanos , Síndrome Metabólica/sangue , Pessoa de Meia-Idade , Fatores de Risco , Vitamina D/análogos & derivados , Vitamina D/sangueRESUMO
OBJECTIVE: To determine the accuracy of various cone beam computed tomography (CBCT) devices in assessing the buccal bone in anterior teeth. MATERIAL AND METHODS: A skull encased in tissue equivalent material was imaged with six CBCT devices: 3D Accuitomo 170 (J. Morita, Japan), CS 9000 3D (Carestream Dental, France), CS 9300 (Carestream Dental, France), Eagle 3D (Dabi Atlante, Brazil), i-CAT Classic (Imaging Sciences International, USA) and Orthophos XG 3D (Sirona Dental System, USA). The exposure and acquisition protocols were determined using the manufacturer's guidelines, the voxel size adjusted as close as possible to 0.2 mm. Cross-sectional images were evaluated randomly, and the buccal bone was assessed. RESULTS: The statistics were calculated based on a logistic regression model with the significance level set at 5%. All CBCT devices showed high accuracy; however, observers noted that the accuracy and sensitivity of CS 9300 device were slightly superior. CONCLUSION: The diagnostic performance of all CBCT devices was high for the evaluation of buccal bone in anterior teeth. When the clinical usefulness of an imaging modality is equivalent, the choice of appropriate imaging should be directed towards the modality that delivers the least radiation dose to the patient for a specific diagnostic task.